Locatelli V, Petraglia F, Penalva A, Panerai A E
Life Sci. 1983 Oct 24;33(17):1711-7. doi: 10.1016/0024-3205(83)90728-2.
Beta-endorphin concentrations have been evaluated in the hypothalamus, pituitary lobes and plasma after 1-and 3-week treatment with 2-Br-alpha-ergocriptine or lisuride, two potent dopaminergic drugs. Hypothalamic beta-endorphin concentrations were significantly decreased after the administration of the dopaminergic agents for 1 or 3 weeks. Similarly, beta-endorphin concentrations decreased in the neurointermediate lobe and plasma. After gel chromatography, it appeared that in the anterior pituitary, beta-lipotropin concentrations were unchanged or lightly increased concomitantly with a decrease of beta-endorphin. Our data indicate that, both in the hypothalamus and the neurointermediate pituitary lobe, beta-endorphin is under an inhibitory dopaminergic tone. The latter may also play a role in inhibiting beta-endorphin cleavage from beta-lipotropin in the anterior pituitary.
在用两种强效多巴胺能药物2-溴-α-麦角隐亭或利苏瑞ide治疗1周和3周后,对下丘脑、垂体叶和血浆中的β-内啡肽浓度进行了评估。给予多巴胺能药物1周或3周后,下丘脑β-内啡肽浓度显著降低。同样,神经中间叶和血浆中的β-内啡肽浓度也降低。凝胶色谱分析后发现,在前叶垂体中,β-促脂素浓度不变或略有升高,同时β-内啡肽浓度降低。我们的数据表明,在下丘脑和神经中间垂体叶中,β-内啡肽都处于多巴胺能抑制性调节之下。后者可能也在抑制前叶垂体中β-促脂素裂解产生β-内啡肽的过程中发挥作用。